Dihydroberberine (DHB): Absorption Studies, Evidence Gaps and Safety
Quick answer. Dihydroberberine (DHB) is a chemically reduced form of berberine that the body turns back into berberine. Two small studies, of 5 and 9 healthy volunteers, found more blood berberine after DHB than after the comparison product; the gap varied widely, and the largest came from a trial funded by the ingredient's maker. No published trial has tested whether DHB itself changes blood sugar, cholesterol or weight; those findings come from ordinary berberine. Berberine slows several drug-processing enzymes and should not be used in pregnancy, while breastfeeding or in infants; anyone on prescription medicine should ask a doctor or pharmacist first.
What dihydroberberine is
Berberine is an alkaloid found in plants such as barberry, goldenseal and Oregon grape, according to the NIH National Center for Complementary and Integrative Health (NCCIH). Dihydroberberine (also dihydro-berberine or dhBBR) is a hydrogenated, or chemically reduced, form of it. DHB occurs in Phellodendron bark, a traditional Chinese medicine, and gut bacteria can make it from berberine.
DHB in supplements is made chemically from berberine. In the first human study, the DHB was made by NNB Nutrition of Nanjing, China, from plant-extracted berberine by a patented process; the company markets it as GlucoVantage®.
Swallowed berberine is poorly absorbed. In a 2015 rat study, DHB gave about five times (4.8-fold) more blood berberine than the same dose of berberine, turning back into berberine in the intestinal tissue, so human studies of DHB measure mainly blood berberine.
What human studies have tested
The first two rows are the only published human studies that gave people DHB; the others tested ordinary berberine, which claims about DHB borrow from.
| Study | Who took part | Form and daily amount | Duration | What was measured | Result |
|---|---|---|---|---|---|
| Moon et al., 2022 (randomized, double-blind, placebo-controlled crossover pilot; US) | 5 healthy, physically active men, average age 26 | In turn, taken 3 times on day 1 and once the next morning: 100 mg DHB (300 mg on day 1), 200 mg DHB (600 mg), 500 mg berberine (1,500 mg), or placebo; DHB was GlucoVantage | About 1 day per product; blood drawn for 2 hours after a test meal eaten about 30 minutes after the last dose | Blood berberine, glucose and insulin after a test meal; routine safety blood tests; side effects | Berberine exposure over 2 hours: 284 after 100 mg DHB and 929 after 200 mg DHB, vs 42 after berberine and 20 after placebo (ng/mL × 120 min). Glucose and insulin did not differ. Funded by NNB Nutrition; the senior author was a paid NNB advisor |
| Chang et al., 2024 (randomized, double-blind, parallel pilot; Canada) | 9 healthy adults | One dose of a store-bought DHB product (100 mg DHB plus 5 mg black pepper extract per capsule) or micellar berberine (250 mg per capsule); number of capsules not reported | 24 hours | Blood berberine and its breakdown products | Berberine exposure 41.1 vs 26.0 ng·h/mL, about 1.6 times higher after DHB but not statistically significant. Berberine peaked about 1 hour after DHB vs 11 hours after micellar berberine. No side effects reported. Funded by ISURA, a non-profit; one co-author is from the company group that supplied the micellar product, which is also the registered sponsor |
| Zhao et al., 2023 (meta-analysis of randomized, placebo-controlled trials; berberine, not DHB) | 20 trials, 1,761 adults with and without diabetes | Berberine, doses varied | Varied | Fasting glucose, A1c, insulin | Fasting glucose −0.52 mmol/L (about −9 mg/dL); A1c −4.48 mmol/mol (about −0.4 percentage points). Larger drops in people with diabetes |
| Blais et al., 2023 (meta-analysis of randomized, placebo-controlled trials; berberine) | 18 trials, 1,788 adults; 15 trials in mainland China or Hong Kong | Berberine, doses varied | 4–24 weeks | Blood lipids; stomach and muscle side effects | LDL cholesterol −0.46 mmol/L (about −18 mg/dL), triglycerides −0.34 mmol/L (about −30 mg/dL). Stomach side effects in 2–23% on berberine vs 2–15% on placebo |
| Hernandez et al., 2024 (meta-analysis of randomized trials; berberine alone or in combination products) | 41 trials, 4,838 people with high blood lipids | Berberine alone or combined with other ingredients | 8–18 weeks | Blood lipids | Berberine alone lowered total cholesterol by 12.1 mg/dL and triglycerides by 17.4 mg/dL; its LDL drop (9.3 mg/dL) was not statistically significant. Combination products showed larger drops |
| Elahi Vahed et al., 2026 (meta-analysis of randomized trials; berberine) | 23 articles of trials in adults | Berberine, doses varied | Varied | Weight, BMI, waist measures | Weight −0.88 kg; BMI −0.48; waist circumference smaller (units misprinted in the abstract); waist-to-hip ratio unchanged. Authors called for better reporting of product purity and dose, and for proper blinding and randomization |
| Guo et al., 2012 (randomized crossover; berberine) | 17 healthy Chinese men | 300 mg berberine 3 times a day (900 mg) | 14 days | Activity of liver enzymes (CYPs) that process drugs, using test drugs | Lower activity of CYP2D6, CYP2C9 and CYP3A4; blood levels of the CYP3A4 test drug midazolam rose 40% |
What the findings suggest
Absorption. In the 5-man study, average exposure after 100 mg of DHB was roughly 7 times that after 500 mg of berberine, and after 200 mg roughly 22 times (our calculation from the published averages). Results varied widely: two very high readings pull the 200 mg average up, and the 100 mg and 200 mg results did not differ significantly. Against micellar berberine the gap was 1.6-fold and could have been chance; blood DHB itself stayed low, consistent with DHB acting as a carrier for berberine. Evidence strength: preliminary.
Blood sugar and insulin. No published trial has tested DHB on fasting glucose, A1c or insulin over weeks; the one DHB study that measured glucose found no change in 5 healthy men over about a day. Berberine trials show small drops in fasting glucose and A1c: NCCIH describes "a modest effect on lowering blood glucose levels in people with type 2 diabetes," and a 2023 umbrella review said these effects still need confirming in high-quality trials. Evidence strength: none in people for DHB; modest for berberine.
Cholesterol and triglycerides. We found no human data for DHB; in mice bred to develop artery plaque, it reduced plaque size while berberine did not. For berberine, one meta-analysis found small drops in LDL cholesterol and triglycerides; another found no significant LDL drop for berberine alone. Evidence strength: none for DHB; small and inconsistent for berberine. (We compare berberine with omega-3s in Berberine vs Omega-3.)
Weight and appetite. We found no human data for DHB; in high-fat-fed rodents, it limited fat gain and insulin resistance. Berberine trials found an average weight difference of under 1 kg, and NCCIH says the evidence "is not conclusive." Evidence strength: none for DHB; weak for berberine.
How it might work. In rat muscle cells, berberine and DHB blocked mitochondrial complex I, which switches on the energy-sensing enzyme AMPK; in insulin-making cells and mice, DHB acted on glucokinase, an enzyme that helps trigger insulin release. Neither has been shown in people.
Where the evidence is limited or conflicting
- Few people, short exposure. Fewer than 15 people have taken DHB in published studies, for about a day at most, against two different comparison products. A 2026 review concluded that human trials of disease outcomes "remained highly limited."
- The "five times" figure. It comes from rat studies, not people; the European Food Safety Authority (EFSA) repeats it as a rat finding in a 2026 draft opinion. Neither human study measured a five-fold difference.
- Registered trials without results. Nanjing Nutrabuilding Bio-tech, listed in U.S. trademark records as the owner of GlucoVantage, sponsors two placebo-controlled trials of 400 mg a day: 54 adults with prediabetes for 6 weeks (primary completion January 2026, still listed as recruiting) and 120 adults with overweight or mild obesity for 12 weeks (listed as not yet recruiting, though its planned completion, September 2026, has passed). Neither record has posted results or been updated since January 2026. A third trial, at Queen's University in Canada with a company collaborator, gave 20 healthy adults one 200 mg DHB dose with green coffee extract; it finished in May 2024, and we found no results or paper.
What buyers say, and what the research shows
Our team analyzed about 1,030 public Amazon reviews of 10 dihydroberberine products, collected in September 2026, after excluding 26 reviews on our own listing that were linked, or appeared to be linked, to creator campaigns. Vinatura's listing is one of the 10; the counts below are of the other 9. Themes were found by keyword matching, weighted by helpful votes, and counted as common on a product when they made up at least 10% of the weighted mentions in its positive or critical reviews. Critical reviews are over-represented, so the sample shows themes, not rates, and what buyers believe or report, not what a product caused.
Belief: DHB is absorbed much better than regular berberine. Better absorption was a common positive theme on 7 of the 9 products. Both studies found higher blood berberine after DHB, but no study has shown that this leads to better results.
Belief: DHB is easier on the stomach than berberine. "Gentle on the stomach" was a common positive theme on 4 of the 9 products, and switching from regular berberine on 7. Yet stomach side effects were a common complaint on 7, and reactions such as dizziness or hives on 5. In the 5-man study, side effects occurred in every phase, including placebo, and numbers that small cannot show which product is gentler.
Belief: DHB lowers blood sugar. Blood sugar was a common positive theme on 8 of the 9 products, and "did not work" a common complaint on 7. The blood sugar evidence comes from berberine trials, not DHB, and a before-and-after meter reading cannot show what caused a change; diabetes and prediabetes need a doctor's diagnosis and care.
Belief: DHB curbs appetite and helps with weight loss. Weight and appetite were a common positive theme on all 9 products, though no DHB trial has tested either.
Belief: DHB can be taken alongside, or instead of, prescription medicines. Medicines or a doctor were a common positive theme on 5 of the 9 products, and some reviews described DHB as an add-on to, or substitute for, metformin or GLP-1 medicines. No published study has tested DHB with a medicine, and every DHB-only trial we found excluded people on glucose-lowering drugs. Never stop or replace a prescribed medicine without your prescriber.
Safety
In DHB studies. In the 5-man study, 2 participants reported 11 side effects: 6 on 100 mg DHB, 1 on 200 mg DHB, 1 on berberine and 3 on placebo; 10 were mild. The 9-person study reported none. In toxicology tests that the ingredient's maker says it sponsored, written up by authors from a consulting firm, DHB did not damage genes in standard bacterial, cell and rodent tests, and rats given 100 mg per kg of body weight a day for 90 days, the highest dose tested, showed no adverse effects. There are no long-term human safety data.
Heart rhythm. In lab studies, DHB blocked the hERG potassium channel in human cells, more strongly than berberine in one comparison; blocking this channel can lengthen the QT interval on an ECG and trigger dangerous rhythms. A 2026 case report described a 61-year-old man with recurrent torsades de pointes, a life-threatening rhythm, while taking berberine, DHB, turmeric and quercetin and with low magnesium; his QT interval returned to normal after treatment and stopping the supplements. A case report cannot prove cause.
Interactions with medicines. We found no human interaction study of DHB; because it turns into berberine, berberine's interactions are the best guide, by inference. In healthy men, 900 mg of berberine a day for 2 weeks lowered the activity of the drug-processing enzymes CYP2D6, CYP2C9 and CYP3A4. In kidney-transplant recipients, berberine left blood levels of the anti-rejection drug cyclosporine about 29% higher, an interaction NCCIH also lists. In 60 healthy adults, by contrast, berberine did not change blood levels of simvastatin or fenofibrate. In cell and rat studies, DHB blocked OATP1B1, a liver transporter that carries some drugs; this is untested in people.
Who should be careful. NCCIH says "People who are pregnant or breastfeeding should not use berberine, and it should not be given to infants," because it can cause or worsen newborn jaundice. France's food safety agency (ANSES) warns that berberine can lower blood sugar and blood pressure, and advises children, adolescents, people with diabetes and people with liver or heart disorders to avoid berberine supplements. Anyone on prescription medicines, especially cyclosporine or diabetes or blood pressure drugs, or with a heart rhythm disorder, should ask a doctor or pharmacist first.
Upper limits. No official body has set a safe intake for DHB. In a 2026 draft opinion for public consultation, EFSA concluded that "no safe intake can currently be established" for berberine-containing plant preparations, citing insufficient data and a genotoxicity concern for berberine in lab tests that still needs confirming in animals; we found no final opinion. In 2019, ANSES could not set a toxicity reference value and gave only a temporary indicative value of 1.7 micrograms per kilogram of body weight a day, far below supplement amounts.
What research does not establish
- That DHB lowers blood sugar, A1c, cholesterol or body weight in people.
- That higher blood berberine after DHB gives better results than ordinary berberine.
- That any amount of DHB, including 250 mg, matches a given dose of berberine.
- That DHB is gentler on the stomach than berberine.
- That DHB is safe over months, in pregnancy, or with prescription medicines.
How we reviewed the evidence
On October 25, 2026, we searched PubMed for dihydroberberine (61 records, all screened by title and abstract), its other names and brand name (49), berberine meta-analyses on glucose, lipids and weight (39), and berberine drug-interaction studies (17). We included every human study that gave people DHB, plus berberine meta-analyses, interaction studies and case reports, and used animal and lab studies only for mechanisms and safety signals; we excluded other berberine derivatives. We read full texts of the two DHB studies and the berberine enzyme study, abstracts otherwise, and funding statements on publishers' pages. On ClinicalTrials.gov we read the five records found for dihydroberberine, GlucoVantage and its maker. We also read NCCIH's two berberine pages, ANSES's 2019 notice, the summary and opening sections of EFSA's 2026 draft opinion and its meeting slides, and the U.S. trademark record for GlucoVantage. Vinatura did not run any of these studies.
Vinatura Research Perspective
We asked five questions of the DHB research: what was measured (blood berberine or a health outcome), in how many people, for how long, compared with what, and who paid. The answers show how narrow the base for the "better absorption" claim is: fewer than 15 healthy volunteers, about a day each; a large difference from a 2-hour sampling window in a trial funded by the ingredient's maker; and a smaller one, possibly chance, in a trial whose registered sponsor supplied the competing micellar form. Neither tested 250 mg or a health effect. Claims online that DHB lowers blood sugar, cholesterol or weight rest on berberine trials, commonly of 1,000–1,500 mg a day for months, that no DHB study has repeated, and its safety advice is borrowed from berberine too.
Our assessment: preliminary evidence that DHB raises blood berberine more than standard berberine for a short time; no published human evidence on blood sugar, lipids, weight or appetite; and no long-term safety or interaction data. Full publication of the trials registered by the GlucoVantage trademark owner, including any null results, would change this assessment, as would an independently funded, multi-day study of at least 20 people comparing DHB at label amounts with 1,000–1,500 mg of berberine, with 24-hour blood sampling, side-effect tracking and an interaction arm.
Where this ingredient appears in Vinatura products
DihydroBerberine with Ceylon Cinnamon contains 250 mg dihydroberberine (GlucoVantage®) and 250 mg Ceylon cinnamon (Cinnamomum verum) per capsule; a serving is 1 capsule, and a bottle holds 30 capsules. The studies above did not test this product. No published human study used 250 mg of DHB or combined DHB with cinnamon.
Frequently asked questions
Is dihydroberberine the same as berberine? No. It is a reduced form that the body converts back into berberine, which is mostly what blood tests find after DHB.
How much DHB did studies use? 100 or 200 mg per dose, 4 times over about a day, or one dose of a 100 mg-per-capsule product; the unpublished registered trials use 400 mg a day. These are study amounts, not recommendations; follow your product label and ask a healthcare professional. See also How much dihydroberberine per day.
Can I take DHB with metformin, a GLP-1 medicine or other prescriptions? No published study has tested this. Berberine, which DHB becomes, slows several drug-processing enzymes and can lower blood sugar and blood pressure, so ask your doctor or pharmacist first.
References
- Moon JM, et al. Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: a randomized, controlled, crossover pilot trial. Nutrients. 2022;14(1):124. doi:10.3390/nu14010124
- Chang C, et al. Differences in metabolite profiles of dihydroberberine and micellar berberine in Caco-2 cells and humans: a pilot study. Int J Mol Sci. 2024;25(11):5625. doi:10.3390/ijms25115625
- Feng R, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015;5:12155. doi:10.1038/srep12155
- Tan L, et al. Dihydroberberine, a hydrogenated derivative of berberine firstly identified in Phellodendri Chinese Cortex, exerts anti-inflammatory effect via dual modulation of NF-κB and MAPK signaling pathways. Int Immunopharmacol. 2019;75:105802. doi:10.1016/j.intimp.2019.105802
- Turner N, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008;57(5):1414-1418. doi:10.2337/db07-1552
- Zhang C, et al. Dihydroberberine normalizes insulin secretion by regulating glucokinase. Diabetes Obes Metab. 2026;28(1):151-165. doi:10.1111/dom.70171
- Chen J, et al. Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE(-/-) mice. J Transl Med. 2014;12:326. doi:10.1186/s12967-014-0326-7
- Wang D, et al. Dihydroberberine in metabolic disorders: bioavailability, molecular mechanisms, toxicology, and future perspectives. Food Chem Toxicol. 2026;216:116267. doi:10.1016/j.fct.2026.116267
- Lewis KD, Falk M. Toxicological assessment of dihydroberberine. Food Chem Toxicol. 2022;168:113301. doi:10.1016/j.fct.2022.113301
- Yu D, et al. Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells. PLoS One. 2017;12(8):e0181823. doi:10.1371/journal.pone.0181823
- Schramm A, et al. HERG channel inhibitors in extracts of Coptidis rhizoma. Planta Med. 2011;77(7):692-697. doi:10.1055/s-0030-1270920
- Mohammadi A, et al. Recurrent torsades de pointes precipitated by berberine supplement. JACC Case Rep. 2026:110193. doi:10.1016/j.jaccas.2026.110193
- Sun Y, et al. Inhibitory effects of alkaloids on OATP1B1 in vitro and in vivo: prediction for food/herb-drug interactions and hepatoprotective effects based on structure-activity relationships. Chem Res Toxicol. 2025;38(2):281-295. doi:10.1021/acs.chemrestox.4c00418
- Zhao JV, et al. Overall and sex-specific effect of berberine on glycemic and insulin-related traits: a systematic review and meta-analysis of randomized controlled trials. J Nutr. 2023;153(10):2939-2950. doi:10.1016/j.tjnut.2023.08.016
- Li Z, et al. Berberine and health outcomes: an umbrella review. Phytother Res. 2023;37(5):2051-2066. doi:10.1002/ptr.7806
- Blais JE, et al. Overall and sex-specific effect of berberine for the treatment of dyslipidemia in adults: a systematic review and meta-analysis of randomized placebo-controlled trials. Drugs. 2023;83(5):403-427. doi:10.1007/s40265-023-01841-4
- Hernandez AV, et al. Impact of berberine or berberine combination products on lipoprotein, triglyceride and biological safety marker concentrations in patients with hyperlipidemia: a systematic review and meta-analysis. J Diet Suppl. 2024;21(2):242-259. doi:10.1080/19390211.2023.2212762
- Elahi Vahed I, et al. The effect of berberine on obesity indices: a systematic review and meta-analysis. Int J Obes (Lond). 2026;50(1):53-73. doi:10.1038/s41366-025-01943-x
- Guo Y, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217. doi:10.1007/s00228-011-1108-2
- Wu X, et al. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-572. doi:10.1007/s00228-005-0952-3
- Li G, et al. Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects. Drug Des Devel Ther. 2019;13:129-139. doi:10.2147/DDDT.S185487
- National Center for Complementary and Integrative Health (NCCIH). In the News: Berberine. Last updated June 2023. nccih.nih.gov
- National Center for Complementary and Integrative Health (NCCIH). Berberine and Weight Loss: What You Need To Know. Last updated November 2023. nccih.nih.gov
- ANSES (French Agency for Food, Environmental and Occupational Health & Safety). Use of berberine-containing plants in food supplements. November 25, 2019. anses.fr
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Draft scientific opinion on the safety of plant preparations containing berberine (EFSA-Q-2022-00803), endorsed for public consultation January 29, 2026. connect.efsa.europa.eu
- EFSA. Targeted stakeholder meeting with food business representatives on EFSA's draft opinion on plant preparations containing berberine. April 22, 2026 (event page and slides). efsa.europa.eu
- NNB Nutrition. NNB released its safety assessment of GlucoVantage (DHB). August 19, 2022. nnbnutrition.com
- U.S. Patent and Trademark Office. GLUCOVANTAGE, Serial No. 87004949, Reg. No. 5360666. Trademark Status & Document Retrieval. Accessed October 25, 2026. tsdr.uspto.gov
- ClinicalTrials.gov. Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia, NCT05021341. Accessed October 25, 2026. clinicaltrials.gov
- ClinicalTrials.gov. Metabolic Differences Between Dihydroberberine and Micellar Berberine in Humans, NCT06202157. Accessed October 25, 2026. clinicaltrials.gov
- ClinicalTrials.gov. Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes, NCT07210684. Accessed October 25, 2026. clinicaltrials.gov
- ClinicalTrials.gov. Dihydroberberine Effects on Body Composition and Metabolic Health in Healthy Adults, NCT07322679. Accessed October 25, 2026. clinicaltrials.gov
- ClinicalTrials.gov. The Effect of Green Coffee Extract With Alpha-lipoic Acid or Dihydroberberine on Blood Glucose Homeostasis in Healthy Adults, NCT06137066. Accessed October 25, 2026. clinicaltrials.gov
Editorial note: This article reviews published research for educational purposes. It does not establish the effects or safety of any specific supplement, including Vinatura products, and is not medical advice. Written by Vinatura Editorial Team. Last reviewed October 2026.
Author
Product Disclaimer
Including an ingredient or study does not evaluate, endorse, or recommend any Vinatura product or any third-party product. Some ingredients discussed may not be used in any Vinatura product.
The content of the articles has not been evaluated by the Food and Drug Administration (FDA) and is not intended to promote or endorse any specific product. Any products sold on this website are not intended to diagnose, treat, cure, or prevent any disease.
Opinions and Endorsements
Any claims, statements, or opinions expressed in the articles are those of the author(s) and do not necessarily reflect the views or opinions of the manufacturers of the dietary supplement products. The products sold on this website are separate from the content of the articles and are not directly endorsed or associated with the information presented here.
Liability Disclaimer
The author(s) of the articles, website, and manufacturers of the dietary supplement products do not assume any liability for any potential consequences arising from the use of the information provided in the articles. Ingredient effects, dosages, and safety vary by individual, formulation, and context; some ingredients interact with medications or may be unsuitable during pregnancy or lactation. It is recommended that individuals consult with a qualified healthcare professional before making any dietary or lifestyle changes, including the use of dietary supplements.
Product Usage
Please refer to the product labels and packaging for specific usage instructions and guidelines for the dietary supplement products sold on this website.
Customer Support
For any concerns or questions regarding the dietary supplement products, please contact our customer support team, who will be more than happy to assist you.
Leave a Comment
Be the first to comment.
What do you think?